stockrowDyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Return on invested capital
Dyne Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −1,956.3%, up 833.7 percentage points from fiscal 2025 (−2,790.0%). Over the past ten years it has ranged from −2,790.0% (fiscal 2025) to 0.00% (fiscal 2024) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −2,790.0% | (2,790.00) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 480.77 |
| FY2022 | −480.8% | (20.44) |
| FY2021 | −460.3% | (460.33) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 18.6% |
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.00% |
| VRDN Viridian Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| DNLI Denali Therapeutics Inc. compare | −80.0% |
| DYN Dyne Therapeutics, Inc. | −1,956.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)